Xencor Stock Price Target and Analyst Ratings (NASDAQ:XNCR)

Analyst Price Target for XNCR

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$43.11

▼ -11.11% Downside Potential

This price target is based on 9 analysts offering 12 month price targets for Xencor in the last 3 months. The average price target is $43.11, with a high forecast of $56.00 and a low forecast of $21.00. The average price target represents a -11.11% upside from the last price of $48.50.

Buy

The current consensus among 9 investment analysts is to buy stock in Xencor. This rating has held steady since July 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
8 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

8/2/2019

0 strong buy ratings
8 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

10/31/2019

0 strong buy ratings
8 buy ratings
1 hold ratings
1 sell ratings

Ratings as of

1/29/2020

0 strong buy ratings
8 buy ratings
1 hold ratings
2 sell ratings

Ratings as of

4/28/2020

0 strong buy ratings
7 buy ratings
1 hold ratings
3 sell ratings

Ratings as of

7/27/2020

0 strong buy ratings
6 buy ratings
0 hold ratings
2 sell ratings

Ratings as of

10/25/2020

0 strong buy ratings
7 buy ratings
0 hold ratings
2 sell ratings

Ratings as of

12/24/2020

0 strong buy ratings
7 buy ratings
0 hold ratings
2 sell ratings

Ratings as of

1/23/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
11/16/2020	Cantor Fitzgerald	Boost Price Target	Overweight	$40.00 ➝ $56.00	Low	i Rating by A. Young at Cantor Fitzgerald
11/6/2020	SVB Leerink	Boost Price Target	Outperform	$42.00 ➝ $46.00	High	i
9/8/2020	SVB Leerink	Lower Price Target	Outperform	$42.00 ➝ $39.00	High	i
8/5/2020	SVB Leerink	Lower Price Target	Outperform	$44.00 ➝ $42.00	Low	i
8/5/2020	Mizuho	Reiterated Rating	Buy		Low	i Rating by Mara Goldstein at Mizuho
7/21/2020	Mizuho	Reiterated Rating	Buy	$52.00	Low	i Rating by Mara Goldstein at Mizuho
7/8/2020	Piper Sandler	Reiterated Rating	Buy	$46.00	Medium	i Rating by Edward Tenthoff at Piper Sandler
7/8/2020	Mizuho	Reiterated Rating	Buy	$52.00	Medium	i Rating by Mara Goldstein at Mizuho
5/13/2020	Canaccord Genuity	Reiterated Rating	Buy	$52.00	Medium	i
5/10/2020	Nomura	Reiterated Rating	Sell	$21.00	High	i
5/7/2020	Mizuho	Reiterated Rating	Buy	$52.00	High	i Rating by Mara Goldstein at Mizuho
3/4/2020	Barclays	Initiated Coverage	Underweight	$28.00	High	i
2/25/2020	Guggenheim	Upgrade	Neutral ➝ Buy	$43.00	High	i Rating by Etzer Darout at Guggenheim
2/17/2020	Mizuho	Reiterated Rating	Buy	$52.00	Medium	i Rating by Mara Goldstein at Mizuho
1/30/2020	Royal Bank of Canada	Initiated Coverage	Outperform	$44.00	High	i
12/18/2019	Mizuho	Reiterated Rating	Buy	$52.00	Medium	i
11/20/2019	Guggenheim	Initiated Coverage	Hold		High	i Rating by Etzer Darout at Guggenheim
11/6/2019	SVB Leerink	Lower Price Target	Outperform	$52.00 ➝ $44.00	Medium	i Rating by Jonathan Chang at SVB Leerink LLC
11/5/2019	Mizuho	Reiterated Rating	Buy		Medium	i Rating by Mara Goldstein at Mizuho
8/8/2019	Nomura Securities	Reiterated Rating	Sell	$21.00	Low	i
8/8/2019	Canaccord Genuity	Boost Price Target	Buy	$45.00 ➝ $52.00	High	i
8/7/2019	SVB Leerink	Set Price Target	Buy	$52.00	Low	i Rating by Jonathan Chang at SVB Leerink LLC
8/7/2019	Raymond James	Reiterated Rating	Outperform ➝ Market Perform		High	i
8/7/2019	Wedbush	Boost Price Target	Outperform	$43.00 ➝ $54.00	High	i
8/7/2019	Guggenheim	Downgrade	Buy ➝ Neutral		High	i
7/8/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$56.00 ➝ $67.00	Low	i
7/1/2019	Mizuho	Reiterated Rating	Buy	$52.00	High	i Rating by Mara Goldstein at Mizuho
6/12/2019	Mizuho	Initiated Coverage	Buy ➝ Buy	$52.00	Medium	i
5/12/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$40.00	High	i Rating by A. Young at Cantor Fitzgerald
4/12/2019	Guggenheim	Initiated Coverage	Buy	$42.00	Low	i
4/2/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$40.00	Low	i Rating by A. Young at Cantor Fitzgerald
3/27/2019	Berenberg Bank	Initiated Coverage	Buy ➝ Buy	$45.00	Low	i
3/14/2019	Raymond James	Initiated Coverage	Outperform ➝ Outperform	$27.85	High	i
2/26/2019	Piper Jaffray Companies	Boost Price Target	Overweight	$56.00	Medium	i
2/22/2019	Nomura Securities	Downgrade	Neutral ➝ Reduce	$28.00 ➝ $21.00	High	i
2/5/2019	Cantor Fitzgerald	Reiterated Rating	Buy	$40.00	High	i Rating by A. Young at Cantor Fitzgerald
12/7/2018	Wedbush	Boost Price Target	Outperform ➝ Outperform	$42.00 ➝ $44.00	Medium	i
11/23/2018	Cantor Fitzgerald	Reiterated Rating	Overweight		High	i Rating by A. Young at Cantor Fitzgerald
11/6/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$40.00	High	i
10/8/2018	Wedbush	Reiterated Rating	Outperform	$42.00	Low	i
9/10/2018	BTIG Research	Initiated Coverage	Buy ➝ Buy	$56.00	High	i
8/8/2018	Canaccord Genuity	Boost Price Target	Buy	$38.00 ➝ $45.00	Medium	i
8/7/2018	Piper Jaffray Companies	Reiterated Rating	Top Pick ➝ Overweight		High	i
6/7/2018	BTIG Research	Initiated Coverage	Buy	$56.00	Low	i
5/9/2018	Canaccord Genuity	Boost Price Target	Buy ➝ Buy	$36.00 ➝ $38.00	Medium	i
4/5/2018	Nomura Securities	Lower Price Target	Neutral	$28.00	Low	i
3/29/2018	Cantor Fitzgerald	Reiterated Rating	Buy	$37.00	Low	i Rating by W. Tanner at Cantor Fitzgerald
3/28/2018	SVB Leerink	Reiterated Rating	Outperform ➝ Outperform	$36.00	Low	i Rating by J. Chang at SVB Leerink LLC
3/19/2018	Wedbush	Boost Price Target	Outperform	$38.00 ➝ $39.00	Low	i
3/1/2018	Cantor Fitzgerald	Reiterated Rating	Overweight	$37.00	High	i Rating by W. Tanner at Cantor Fitzgerald
2/22/2018	Cantor Fitzgerald	Initiated Coverage	Buy	$33.00	Low	i Rating by W. Tanner at Cantor Fitzgerald
11/29/2017	Cantor Fitzgerald	Initiated Coverage	Overweight	$33.00	Medium	i Rating by W. Tanner at Cantor Fitzgerald
11/12/2017	Piper Jaffray Companies	Reiterated Rating	Buy	$35.00	N/A	i
10/23/2017	Canaccord Genuity	Set Price Target	Buy	$36.00	N/A	i Rating by Arlinda Lee at Canaccord Genuity
8/8/2017	Canaccord Genuity	Reiterated Rating	Buy	$36.00	High	i
6/16/2017	Wedbush	Reiterated Rating	Outperform	$29.00	Low	i
6/6/2017	Wedbush	Reiterated Rating	Outperform	$29.00	High	i
5/10/2017	Wedbush	Reiterated Rating	Outperform	$29.00	High	i
3/2/2017	Wedbush	Reiterated Rating	Outperform ➝ Outperform	$27.00 ➝ $33.00	N/A	i
3/1/2017	Nomura Instinet	Initiated Coverage	Neutral ➝ Neutral	$21.00	N/A	i
3/1/2017	Nomura Securities	Initiated Coverage	Neutral		N/A	i
11/28/2016	Canaccord Genuity	Set Price Target	Buy	$32.00	N/A	i Rating by Arlinda Lee at Canaccord Genuity
11/14/2016	Canaccord Genuity	Set Price Target	Buy	$27.00	N/A	i Rating by Arlinda Lee at Canaccord Genuity
11/3/2016	SVB Leerink	Reiterated Rating	Buy	$26.00	N/A	i
10/4/2016	Piper Jaffray Companies	Initiated Coverage	Overweight	$35.00	N/A	i
9/12/2016	Canaccord Genuity	Set Price Target	Buy	$27.00	N/A	i Rating by arlinda lee at Canaccord Genuity
9/12/2016	Wedbush	Reiterated Rating	Outperform	$27.00	N/A	i
6/29/2016	SVB Leerink	Reiterated Rating	Outperform	$18.00	N/A	i
6/28/2016	Canaccord Genuity	Reiterated Rating	Buy		N/A	i Rating by Arlinda Lee at Canaccord Genuity
6/28/2016	Wedbush	Reiterated Rating	Outperform	$27.00	N/A	i
5/3/2016	Canaccord Genuity	Reiterated Rating	Buy		N/A	i Rating by Arlinda Lee at Canaccord Genuity
5/2/2016	Oppenheimer	Reiterated Rating	Buy		N/A	i Rating by Christopher Marai at Oppenheimer Holdings Inc.
4/4/2016	Canaccord Genuity	Reiterated Rating	Buy	$20.00	N/A	i Rating by Arlinda Lee at Canaccord Genuity
3/9/2016	Oppenheimer	Reiterated Rating	Outperform	$28.00	N/A	i
3/8/2016	SVB Leerink	Lower Price Target	Outperform	$22.00 ➝ $18.00	N/A	i
3/8/2016	Canaccord Genuity	Reiterated Rating	Buy	$20.00	N/A	i Rating by Arlinda Lee at Canaccord Genuity

(Data available from 1/24/2016 forward)

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases. It develops its antibody product candidates to treat cancer and autoimmune diseases. The company's product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; AIMab7195, which is in development and commercialization stage. Its product candidates also comprise XmAb14045, a bispecific antibody which is in Phase I clinical trial for the treatment of acute myeloid leukemia; plamotamab (XmAb13676) that is in Phase I clinical trial to treat B-cell malignancies; and XmAb18087, which is in Phase I clinical trial for neuroendocrine tumors and gastrointestinal stromal tumors. In addition, the company offers Tafasitamab, an antibody drug candidate for the treatment of patients with relapsed/refractory diffuse; AMG424, a bispecific antibody that targets CD38 and CD3, which is in Phase I clinical trial for the treatment of various myeloma; and AMG509, a bispecific antibody that is in preclinical development stage to treat prostate cancer. Further, it is developing bispecific antibodies to treat various cancers, such as XmAb20717, XmAb22841, and XmAb23104 which are in preclinical Phase. Additionally, it offers XmAb24306, initial cytokine candidate which is in Phase I clinical trial. The company has collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc.; Amgen Inc.; Catalent Pharma Solutions LLC.; Janssen Biotech, Inc.; MorphoSys AG; and Incyte Corporation. Xencor, Inc. was founded in 1997 and is headquartered in Monrovia, California.

Today's Range

Now: $48.50

$46.06

$48.79

50 Day Range

MA: $45.53

$38.85

$49.90

52 Week Range

Now: $48.50

$19.35

$50.56

Volume

201,688 shs

Average Volume

251,292 shs

Market Capitalization

$2.79 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8

Frequently Asked Questions

What sell-side analysts currently cover shares of Xencor?

The following sell-side analysts have issued reports on Xencor in the last year: Barclays PLC, Canaccord Genuity, Cantor Fitzgerald, Guggenheim, Mizuho, Nomura, Piper Sandler, Royal Bank of Canada, SVB Leerink LLC, TheStreet, and Zacks Investment Research.

What is the current price target for Xencor?

9 Wall Street analysts have set twelve-month price targets for Xencor in the last year. Their average twelve-month price target is $43.11, suggesting a possible downside of 11.1%. Cantor Fitzgerald has the highest price target set, predicting XNCR will reach $56.00 in the next twelve months. Nomura has the lowest price target set, forecasting a price of $21.00 for Xencor in the next year.

What is the current consensus analyst rating for Xencor?

Xencor currently has 2 sell ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe XNCR will outperform the market and that investors should add to their positions of Xencor.

What other companies compete with Xencor?

Other companies that are similar to Xencor include Mirati Therapeutics, Zai Lab, Bausch Health Companies, Jazz Pharmaceuticals, Ionis Pharmaceuticals, Ascendis Pharma A/S, Ultragenyx Pharmaceutical, BridgeBio Pharma, Arrowhead Pharmaceuticals, ACADIA Pharmaceuticals, Sarepta Therapeutics, United Therapeutics, Galapagos, Allakos and Schrödinger.

How do I contact Xencor's investor relations team?

Xencor's physical mailing address is 111 WEST LEMON AVENUE, MONROVIA CA, 91016. The biopharmaceutical company's listed phone number is 626-305-5900 and its investor relations email address is [email protected] The official website for Xencor is www.xencor.com.

NASDAQ:XNCR - Xencor Stock Price Target and Predictions

Analyst Price Target for XNCR

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Xencor?

What is the current price target for Xencor?

What is the current consensus analyst rating for Xencor?

What other companies compete with Xencor?

How do I contact Xencor's investor relations team?